| Nov 20 |
Celldex Announces First Patient Dosed in Phase 1 Healthy Volunteer Study of CDX-622, a Bispecific Antibody, for the Treatment of Inflammatory Diseases
|
| Nov 20 |
Beyond The Numbers: 11 Analysts Discuss Celldex Therapeutics Stock
|
| Nov 8 |
Celldex Therapeutics Third Quarter 2024 Earnings: Beats Expectations
|
| Nov 7 |
Celldex GAAP EPS of -$0.64 beats by $0.04, revenue of $3.19M beats by $2.13M
|
| Nov 6 |
Celldex Therapeutics (CLDX) Reports Q3 Loss, Tops Revenue Estimates
|
| Nov 6 |
Celldex: Q3 Earnings Snapshot
|
| Nov 6 |
Celldex Reports Third Quarter 2024 Financial Results and Provides Corporate Update
|
| Nov 4 |
Celldex Therapeutics' Strong Cash Runway Supports Barzolvolimab's Path To Market
|
| Oct 29 |
Celldex selloff creates buying opportunity, says Guggenheim
|
| Oct 28 |
Celldex Therapeutics (NASDAQ:CLDX) pulls back 6.1% this week, but still delivers shareholders fantastic 57% CAGR over 5 years
|
